{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:29:38Z","timestamp":1794954578120,"version":"4.9.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Scientific research project of Science and Technology Department of Henan Province","award":["No. 202102310360"],"award-info":[{"award-number":["No. 202102310360"]}]},{"name":"National Natural Science Foundation of China-Henan Joint Fund Project","award":["U1804177"],"award-info":[{"award-number":["U1804177"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      The aim of this study was to evaluate the predictive factors of central lymph node metastasis (CLNM) and\n                      <jats:italic>BRAF<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>V600E<\/jats:italic>\n                      <\/jats:sup>\n                      mutation in Chinese patients with papillary thyroid carcinoma (PTC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 943 PTC patients who underwent thyroidectomy from 2014 to 2016 at our hospital were enrolled. Those patients were divided into PTC &gt; 10 mm and papillary thyroid microcarcinoma (PTMC) groups by tumor size. The\n                      <jats:italic>BRAF<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>V600E<\/jats:italic>\n                      <\/jats:sup>\n                      mutation was examined by quantitative real-time PCR. Univariate and multivariate analyses were used to examine risk factors associated with CLNM and the\n                      <jats:italic>BRAF<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>V600E<\/jats:italic>\n                      <\/jats:sup>\n                      mutation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The frequency of CLNM was 53% (505\/943). Both univariate and multivariate analyses suggested that the risk factors for CLNM in PTC patients were male, younger age, and larger tumor size (\n                      <jats:italic>P &lt;<\/jats:italic>\n                      0.05). Coexistent Hashimoto thyroiditis (HT) was an independent protective factor against CLNM when the tumor was &gt; 10 mm (\n                      <jats:italic>P =<\/jats:italic>\n                      0.006). Stratified analysis revealed that male, age \u2264 30 years, and tumor size &gt; 5 mm were independent risk factors for CLNM. The\n                      <jats:italic>BRAF<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>V600E<\/jats:italic>\n                      <\/jats:sup>\n                      mutation rate was 85%. Multivariate logistic regression analysis revealed that age (\n                      <jats:italic>P &lt;<\/jats:italic>\n                      0.001) and coexistent HT (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.005) were independent predictive factors of\n                      <jats:italic>BRAF<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>V600E<\/jats:italic>\n                      <\/jats:sup>\n                      mutation in PTC patients. Only age was a risk factor for the\n                      <jats:italic>BRAF<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>V600E<\/jats:italic>\n                      <\/jats:sup>\n                      mutation when the tumor was &gt; 10 mm (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.004). In the PTMC group, the\n                      <jats:italic>BRAF<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>V600E<\/jats:italic>\n                      <\/jats:sup>\n                      mutation was significantly correlated with tumor size (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001) and coexistent HT (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.03). Stratified analysis revealed that age &gt; 30 years and tumor size &gt; 5 mm were independent predictive factors of\n                      <jats:italic>BRAF<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>V600E<\/jats:italic>\n                      <\/jats:sup>\n                      mutation. Furthermore, the incidence of CLNM was significantly higher in\n                      <jats:italic>BRAF<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>V600E<\/jats:italic>\n                      <\/jats:sup>\n                      mutation-positive patients (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.009) when the tumor was \u2264 5 mm.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The factors male, younger age (\u2264 30 years), large tumor size (&gt; 5 mm), and coexistent HT are independent predicative factors for CLNM. The\n                      <jats:italic>BRAF<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>V600E<\/jats:italic>\n                      <\/jats:sup>\n                      mutation is associated with both large size and without HT in PTMC patients, age &gt; 30 years in the PTC &gt; 10 mm group. The\n                      <jats:italic>BRAF<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>V600E<\/jats:italic>\n                      <\/jats:sup>\n                      mutation was an independent risk factor for CLNM when the tumor was \u2264 5 mm. For optimal management, these features should be comprehensively evaluated to determine the initial surgical approach for PTC patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12957-021-02326-y","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T14:11:14Z","timestamp":1626185474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Predicting factors of central lymph node metastasis and BRAFV600E mutation in Chinese population with papillary thyroid carcinoma"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3256-978X","authenticated-orcid":false,"given":"Sheng Li","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Ping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi Guang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen Cong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue Wu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling Fei","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,13]]},"reference":[{"issue":"16","key":"2326_CR1","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1002\/cncr.24416","volume":"115","author":"AY Chen","year":"2009","unstructured":"Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009;115(16):3801\u20137. https:\/\/doi.org\/10.1002\/cncr.24416.","journal-title":"Cancer."},{"issue":"18","key":"2326_CR2","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1001\/jama.295.18.2164","volume":"295","author":"L Davies","year":"2006","unstructured":"Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295(18):2164\u20137. https:\/\/doi.org\/10.1001\/jama.295.18.2164.","journal-title":"JAMA."},{"issue":"6","key":"2326_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin."},{"issue":"11","key":"2326_CR4","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1210\/jc.2008-1328","volume":"93","author":"EK Alexander","year":"2008","unstructured":"Alexander EK. Approach to the patient with a cytologically indeterminate thyroid nodule. J Clin Endocrinol Metab. 2008;93(11):4175\u201382. https:\/\/doi.org\/10.1210\/jc.2008-1328.","journal-title":"J Clin Endocrinol Metab."},{"issue":"20","key":"2326_CR5","first-page":"30062","volume":"S1808-8694","author":"L Jiwang","year":"2020","unstructured":"Jiwang L, Yahong L, Kai L, Bo H, Yuejiao Z, Haotian W, et al. Clinicopathologic factors and preoperative ultrasonographic characteristics for predicting cetral lymph node metastasis in papillary thyroid microcarcinoma: a single center retrospective study. Braz J Otorhinolaryngol. 2020;S1808-8694(20):30062\u20138.","journal-title":"Braz J Otorhinolaryngol"},{"issue":"3","key":"2326_CR6","first-page":"502","volume":"48","author":"YJ Zhang","year":"2016","unstructured":"Zhang YJ, Liu BG, Zhao ZY, Sheng JD, Feng DD. Relationship and clinical significance between mutated BRAF with prophylactic central-neck nodal dissection in papillary thyroid carcinoma. Beijing Da Xue Xue Bao Yi Xue Bao. 2016;48(3):502\u20136.","journal-title":"Beijing Da Xue Xue Bao Yi Xue Bao."},{"issue":"10","key":"2326_CR7","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1007\/s00268-015-3108-3","volume":"39","author":"N Qu","year":"2015","unstructured":"Qu N, Zhang L, Ji QH, Chen JY, Zhu YX, Cao YM, et al. Risk factors for central compartment lymph node metastasis in papillary thyroid microcarcinoma: a meta-analysis. World J Surg. 2015;39(10):2459\u201370. https:\/\/doi.org\/10.1007\/s00268-015-3108-3.","journal-title":"World J Surg."},{"issue":"1","key":"2326_CR8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12957-020-01965-x","volume":"18","author":"Y Dou","year":"2020","unstructured":"Dou Y, Hu D, Chen Y, Xiong W, Xiao Q, Su X. PTC located in the upper pole is more prone to lateral lymph node metastasis and skip metastasis. World J Surg Oncol. 2020;18(1):188. https:\/\/doi.org\/10.1186\/s12957-020-01965-x.","journal-title":"World J Surg Oncol."},{"issue":"1","key":"2326_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.17392\/1086-20","volume":"17","author":"M Celik","year":"2020","unstructured":"Celik M, Bulbul BY, Ayturk S, Durmus Y, Gurkan H, Can N, et al. The relation between BRAFV600E mutation and clinicopathological characteristics of papillary thyroid cancer. Med Glas (Zenica). 2020;17(1):30\u20134. https:\/\/doi.org\/10.17392\/1086-20.","journal-title":"Med Glas (Zenica)."},{"issue":"12","key":"2326_CR10","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.4158\/EP-2018-0305","volume":"24","author":"X Wu","year":"2018","unstructured":"Wu X, Li B, Zheng C, He X. Risk factors for central lymph node metastases in patients with papillary thyroid microcarcinoma. Endocr Pract. 2018;24(12):1057\u201362. https:\/\/doi.org\/10.4158\/EP-2018-0305.","journal-title":"Endocr Pract"},{"issue":"1","key":"2326_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12957-020-01975-9","volume":"18","author":"WP Guo","year":"2020","unstructured":"Guo WP, Tang D, Pang YY, Li XJ, Chen G, Huang ZG, et al. Immunohistochemical basigin expression level in thyroid cancer tissues. World J Surg Oncol. 2020;18(1):240. https:\/\/doi.org\/10.1186\/s12957-020-01975-9.","journal-title":"World J Surg Oncol."},{"issue":"1","key":"2326_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12957-020-01923-7","volume":"18","author":"C Shi","year":"2020","unstructured":"Shi C, Cao J, Shi T, Liang M, Ding C, Lv Y, et al. BRAF V600E mutation, BRAF-activated long non-coding RNA and miR-9 expression in papillary thyroid carcinoma, and their association with clinicopathological features. World J Surg Oncol. 2020;18(1):145.","journal-title":"World J Surg Oncol"},{"issue":"1","key":"2326_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12957-019-1568-x","volume":"17","author":"C Xiao","year":"2019","unstructured":"Xiao C, Huang Y, Gao Q, Feng Z, Li Q, Liu Z. Expression of activator protein-1 in papillary thyroid carcinoma and its clinical significance. World J Surg Oncol. 2019;17(1):25. https:\/\/doi.org\/10.1186\/s12957-019-1568-x.","journal-title":"World J Surg Oncol."},{"issue":"7","key":"2326_CR14","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1210\/er.2007-0007","volume":"28","author":"M Xing","year":"2007","unstructured":"Xing M. BRAFV600E mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28(7):742\u201362. https:\/\/doi.org\/10.1210\/er.2007-0007.","journal-title":"Endocr Rev."},{"issue":"2","key":"2326_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1530\/ERC-14-0531","volume":"22","author":"F Li","year":"2015","unstructured":"Li F, Chen G, Sheng C, Gusdon AM, Huang Y, Lv Z, et al. BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis. Endocr Relat Cancer. 2015;22(2):159\u201368. https:\/\/doi.org\/10.1530\/ERC-14-0531.","journal-title":"Endocr Relat Cancer."},{"issue":"27","key":"2326_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016386","volume":"98","author":"X Wu","year":"2019","unstructured":"Wu X, Li B, Zheng C, He X. Predicting factors of lateral neck lymph node metastases in patients with papillary thyroid microcarcinoma. Medicine (Baltimore). 2019;98(27):e16386. https:\/\/doi.org\/10.1097\/MD.0000000000016386.","journal-title":"Medicine (Baltimore)."},{"issue":"11","key":"2326_CR17","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1515\/jpem-2020-0174","volume":"33","author":"D Chakraborty","year":"2020","unstructured":"Chakraborty D, Shakya S, Ballal S, Agarwal S, Bal C. BRAF V600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation. J Pediatr Endocrinol Metab. 2020;33(11):1465\u201374. https:\/\/doi.org\/10.1515\/jpem-2020-0174.","journal-title":"J Pediatr Endocrinol Metab."},{"issue":"5","key":"2326_CR18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.14639\/0392-100X-1709","volume":"37","author":"J Liang","year":"2017","unstructured":"Liang J, Zeng W, Fang F, Yu T, Zhao Y, Fan X, et al. Clinical analysis of Hashimoto thyroiditis coexistent with papillary thyroid cancer in 1392 patients. Acta Otorhinolaryngol Ital. 2017;37(5):393\u2013400. https:\/\/doi.org\/10.14639\/0392-100X-1709.","journal-title":"Acta Otorhinolaryngol Ital."},{"issue":"5","key":"2326_CR19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/hed.21518","volume":"33","author":"KW Kim","year":"2011","unstructured":"Kim KW, Park YJ, Kim EH, Park SY, Park DJ, Ahn SH, et al. Elevated risk of papillary thyroid cancer in Korean patients with Hashimoto\u2019s thyroiditis. Head Neck. 2011;33(5):691\u20135. https:\/\/doi.org\/10.1002\/hed.21518.","journal-title":"Head Neck."},{"issue":"8","key":"2326_CR20","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3346\/jkms.2012.27.8.883","volume":"27","author":"JS Jeong","year":"2012","unstructured":"Jeong JS, Kim HK, Lee CR, Park S, Park JH, Kang SW, et al. Coexistence of chronic lymphocytic thyroiditis with papillary thyroid carcinoma: clinical manifestation and prognostic outcome. J Korean Med Sci. 2012;27(8):883\u20139. https:\/\/doi.org\/10.3346\/jkms.2012.27.8.883.","journal-title":"J Korean Med Sci."},{"issue":"7","key":"2326_CR21","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1245\/s10434-012-2851-z","volume":"20","author":"X Zheng","year":"2013","unstructured":"Zheng X, Wei S, Han Y, Li Y, Yu Y, Yun X, et al. Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases. Ann Surg Oncol. 2013;20(7):2266\u201373. https:\/\/doi.org\/10.1245\/s10434-012-2851-z.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"2326_CR22","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.yexmp.2014.08.005","volume":"97","author":"S Liu","year":"2014","unstructured":"Liu S, Gao A, Zhang B, Zhang Z, Zhao Y, Chen P, et al. Assessment of molecular testing in fine-needle aspiration biopsy samples: an experience in a Chinese population. Exp Mol Pathol. 2014;97(2):292\u20137. https:\/\/doi.org\/10.1016\/j.yexmp.2014.08.005.","journal-title":"Exp Mol Pathol."},{"issue":"2","key":"2326_CR23","first-page":"123","volume":"37","author":"C Shi","year":"2015","unstructured":"Shi C, Qin H, Ding C, Sun Y, Lyu Y, Shi T. Association between BRAF V600E mutation and central lymph node metastasis in patients with papillary thyroid carcinoma. Zhonghua Zhong Liu Za Zhi. 2015;37(2):123\u20137.","journal-title":"Zhonghua Zhong Liu Za Zhi."},{"issue":"5","key":"2326_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3760\/cma.j.issn.0253-3766.2017.05.008","volume":"39","author":"CL Shi","year":"2017","unstructured":"Shi CL, Guo Y, Lyu YC, Nanding ZABYS, Gao WC, Shi TF, et al. Clinical pathological characteristics of resectable papillary thyroid microcarcinoma. Zhonghua Zhong Liu Za Zhi. 2017;39(5):361\u20136. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-3766.2017.05.008.","journal-title":"Zhonghua Zhong Liu Za Zhi."},{"key":"2326_CR25","doi-asserted-by":"publisher","unstructured":"Kim WW, Ha TK,\u00a0Bae SK. Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis. J Otolaryngol Head\u00a0Neck Surg. 2018;47(1):4.\u00a0https:\/\/doi.org\/10.1186\/s40463-017-0247-6.","DOI":"10.1186\/s40463-017-0247-6"},{"key":"2326_CR26","doi-asserted-by":"publisher","unstructured":"Fiore E, Latrofa F, Vitti P. Iodine, thyroid autoimmunity and cancer. Eur Thyroid J. 2015;4(1):26\u201335.\u00a0https:\/\/doi.org\/10.1159\/000371741.","DOI":"10.1159\/000371741"},{"issue":"4","key":"2326_CR27","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1073\/pnas.1015557108","volume":"108","author":"AT Franco","year":"2011","unstructured":"Franco AT, Malaguarnera R, Refetoff S, Liao XH, Lundsmith E, Kimura S, et al. Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci U S A. 2011;108(4):1615\u201320. https:\/\/doi.org\/10.1073\/pnas.1015557108.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"2326_CR28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ecl.2018.10.006","volume":"48","author":"JP Brito","year":"2019","unstructured":"Brito JP, Hay ID. Management of papillary thyroid microcarcinoma. Endocrinol Metab Clin North Am. 2019;48(1):199\u2013213. https:\/\/doi.org\/10.1016\/j.ecl.2018.10.006.","journal-title":"Endocrinol Metab Clin North Am."},{"issue":"12","key":"2326_CR29","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/acem.13065","volume":"23","author":"M Kunneman","year":"2016","unstructured":"Kunneman M, Montori VM, Castaneda-Guarderas A, Hess EP. What is shared decision making? (and What It Is Not). Acad Emerg Med. 2016;23(12):1320\u20134. https:\/\/doi.org\/10.1111\/acem.13065.","journal-title":"Acad Emerg Med."},{"issue":"1","key":"2326_CR30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12957-020-01948-y","volume":"18","author":"W Wang","year":"2020","unstructured":"Wang W, Yang Z, Ouyang Q. A nomogram to predict skip metastasis in papillary thyroid cancer. World J Surg Oncol. 2020;18(1):167. https:\/\/doi.org\/10.1186\/s12957-020-01948-y.","journal-title":"World J Surg Oncol."}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-021-02326-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-021-02326-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-021-02326-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T14:11:58Z","timestamp":1626185518000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-021-02326-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2326"],"URL":"https:\/\/doi.org\/10.1186\/s12957-021-02326-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-142136\/v1","asserted-by":"object"}]},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,13]]},"assertion":[{"value":"5 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Declaration of Helsinki and the Institute Research Ethics Committee of Henan Provincial People\u2019s Hospital. Written informed consent was obtained from all patients included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"211"}}